Yuanshi Technology has completed a Pre-Series A financing of nearly 300 million yuan, driving the continuous evolution of virtual cells with a closed-loop evidence chain.
Recently, AIVC (AI Virtual Cell) enterprise 「MetaIntelli Tech」 announced that it has completed a Pre-A round of financing of nearly 300 million RMB. Previously, the company has successively completed the angel round and angel+ round of financing of nearly 100 million RMB. This round is led by Legend Capital, followed by China V Fund, China Merchants China Direct Investments, JD-associated fund, CDH VGC, CMC Capital, with existing shareholders including Monolith, Sinovation Ventures, DaoTong Capital, Yanyan Venture Capital continuing to increase their investment, Lighthouse Capital acts as the exclusive financial advisor. The funds will be used for data accumulation, automated platform construction, model iteration and team building.
MetaIntelli Tech focuses on AI virtual cells, building the fundamental base of life sciences with "biological raw data engine + general cell model". The company's goal is to enable AI to learn the dynamic causal logic of the life system itself, accurately predict the responses of cells under different disease states, experimental conditions and intervention methods, and build a general large cell model that can continuously understand, reason about, predict cells and self-evolve from experimental feedback.
Whether the general cell model can continue to progress depends critically on whether effective evidence can be continuously obtained. Although a large number of repeated measurements of similar cells can increase the number of samples, they may not fill the information gaps in rare states, key interventions or specific contexts. Valid data requires reliable correlation of cell background, intervention conditions, matched controls and response measurements. The company adopts the "model prediction - experimental verification - data feedback - model update" dry-wet closed loop to enable the model to identify prediction shortcomings, assist in screening more informative experiments, and then use new results to test predictions, supplement data and update the model. Its goal is not to simply expand the amount of data, but to generate new evidence that can be used for training and verification in each round of experiments, which is also a specific embodiment of Recursive Self-Improvement (RSI) in biological foundation models.
Schematic diagram of dry-wet closed loop
The company's core team has cross-disciplinary backgrounds in computational biology and single-cell technology. Dr. Wu Jiaqi, CEO, holds a doctorate in systems biology from Peking University, has engaged in post-doctoral research at The Rockefeller University, and has rich experience in bioinformatics and single-cell sequencing technology development; Dr. Dong Mingze, CTO, completed his undergraduate study at Yuanpei College of Peking University, later obtained his doctorate in computational biology from Yale University, and carried out post-doctoral research at Stanford University. He once participated in the research of STATE, the world's first virtual cell model that comprehensively outperforms the baseline at Arc Institute, and led the release of STACK, the world's first zero-shot generalization SOTA model as the sole first author, and later engaged in cutting-edge AI safety research at Anthropic. At present, Dr. Dong Mingze has joined MetaIntelli Tech full-time, bringing the company's model R&D level to the international cutting edge.
Legend Capital stated: "Life sciences have cross-scale 'emergence', and virtual cells perform mesoscale modeling, which is another upgrade of AI drug discovery after molecular models. The founding team of MetaIntelli Tech has deeply participated in the R&D of cutting-edge virtual cell models such as STATE and STACK, and has accumulated profound experience in models and data. The company is committed to enabling models to understand how cells respond to interventions, which is exactly the key to the next stage of AI drug discovery. We are very pleased to cooperate with the two young scientists and look forward to MetaIntelli growing into a globally influential company."
China V Fund stated: "In our continuous research on cutting-edge AI technologies and investment opportunities, we have seen that top global scientific research and industrial forces, ranging from US national scientific research institutions to the world's top tech companies and multinational pharmaceutical enterprises, are accelerating the layout of cell foundation models. Behind this lies a historic opportunity for artificial intelligence to evolve from understanding language to understanding and predicting life, and then reshape the paradigm of new drug R&D and even the entire life science research. The founders of MetaIntelli Tech, Dong Mingze and Wu Jiaqi, are deeply engaged in cutting-edge cell models and large-scale single-cell experimental technologies respectively, forming a unique complementarity of original algorithms and high-quality data production capabilities. The cross-cell environment training-free migration implemented by Dong Mingze in the STACK model demonstrates the important innovation potential of cell models in generalization capabilities. The return of the two outstanding young scientists to start their businesses shows us the huge potential for China to produce a world-class cell foundation model company."
Wang Xiaoding, Chief Investment Officer of China Merchants China Direct Investments, stated: "Life sciences are a cutting-edge strategic field with national priority layout, and new drug R&D is evolving from the traditional trial-and-error mode to the direction of computable and predictable systems biology. As an emerging technology, virtual cell technology is expected to unlock the underlying operation rules of life and reshape the boundary of human cognition of life systems. China Merchants China Direct Investments is optimistic about the dry-wet closed-loop innovation path of 'data production - AI modeling - wet experiment verification' built by MetaIntelli Tech; at the same time, the joining of Dr. Dong Mingze has injected world-class model R&D strength into the team, which will accelerate the polishing of the general cell foundation model. This investment is not only a strategic layout for cutting-edge hard technologies, but also helps the independent development of the local AI systems biology industry chain. We look forward to the team continuing to dig deep in this field, and promoting AI to upgrade from 'understanding biological sequences' to 'predicting cell fate'."
Gao Jieliang, Senior Partner of CDH VGC, stated: "Virtual cells are becoming an important direction for the deep integration of AI and life sciences, which is expected to promote the paradigm transformation of drug R&D and gradually develop into an important infrastructure for biomedical R&D. MetaIntelli Tech has profound technical accumulation in virtual cell model R&D and high-throughput experimental system construction, and its technical path of collaborative iterative development of models and experiments has long-term value. We are very optimistic about the company's development potential, will continue to support its growth, and look forward to MetaIntelli Tech continuously promoting the deep integration of model capabilities and experimental systems, so as to provide more valuable prediction and decision support for drug R&D."
CMC Capital stated: "AI virtual cell is a vital part of building AI digital life, and has extremely high potential in leading the paradigm transformation of drug R&D. The team of MetaIntelli Tech has a high degree of completeness and development potential, and we look forward to exploring the cutting edge of future development together with the company.